Clinical trialPhase 1Terminated
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
A Phase 1b Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
- Outcome
- Stopped early\<75 % participation (Other)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- 22 January 2024
- Ended
- 15 September 2025
- Enrollment
- 4 participants
- Sites
- 1
- Primary outcomes
- Maximum Tolerated Dose (MTD) and RP2D of YL-13027 in combination with gemcitabine and nab-paclitaxel.; Overall Response Rate (ORR) of YL-13027 in combination with gemcitabine and nab-paclitaxel
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 8 December 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
Primary Objectives 1. To determine the safety and tolerability of YL-13027 in combination with gemcitabine and nab-paclitaxel in participants with refractory metastatic pancreatic cancer. 2. To determine the objective response rate (ORR) of YL-13027 in combination with gemcitabine and nab-paclitaxel in participants with refractory metastatic pancreatic cancer. Secondary Objectives 1. To evaluate other indicators of the antitumor activity of YL-13027 in combination with gemcitabine and nab-paclitaxel. 2. To evaluate the PK of YL-13027 in combination with gemcitabine and nabpaclitaxel. Exploratory Objectives 1. To evaluate the PD effects of YL-13027 in combination with gemcitabine and nabpaclitaxel. 2. To evaluate biomarkers of response and resistance to YL-13027 in combination with gemcitabine and nab-paclitaxel.